Literature DB >> 8840999

Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas.

J E Celis1, M Ostergaard, B Basse, A Celis, J B Lauridsen, G P Ratz, I Andersen, B Hein, H Wolf, T F Orntoft, H H Rasmussen.   

Abstract

Multifocal recurrent papillary tumors provide a unique model system to study the molecular mechanisms underlying the steps involved in transitional cell carcinoma progression and offer a valuable source of material to search for biomarkers that may form the basis for diagnosis, prognosis, and treatment. We have examined the protein expression profiles of normal bladder urothelium and of 63 transitional cell carcinomas of various histopathological grades and T stages using high-resolution, two-dimensional gel electrophoresis, microsequencing, mass spectrometry, and a two-dimensional gel protein database approach for polypeptide identification (http://biobase.dk/cgi-bin/celis). In general, the results revealed a striking similarity between the overall qualitative expression patterns of papillary tumors of all grades, as well as of papillary and solid tumors of grade III. With few exceptions, tumors of grades I-III expressed, albeit at different levels, all of the keratins (7, 8, 13, 17, 18, 19, and 20) found in the normal urothelium. Grade IV tumors lacked or expressed reduced levels of keratin 13 but most resembled low-grade tumors. One invasive grade IV tumor, however, expressed a fibroblast-like protein phenotype. Four proteins that were expressed by normal urothelium and were lost at various stages of progression were identified as glutathione S-transferase mu, prostaglandin dehydrogenase (PGDH), a fatty acid binding protein with homology to the adipocyte isoform (A-FABP), and keratin 13. The percentage of tumors expressing A-FABP was very high in low-grade lesions but decreased drastically (P = 0.0006) in grade III and IV neoplasms. In addition, low-grade tumors contained more A-FABP than their high-grade counterparts. The stage of the disease was also statistically (P = 0.0269) related to the presence or absence of A-FABP in grade III tumors. Similar analysis of glutathione S-transferase mu and PGDH showed a statistically significant decrease of these proteins in high-grade (grades III and IV) tumors (P = 0.0026 and P = 0.0044, respectively). Only PGDH showed a suggestive correlation (P = 0.0775) with the stage of the disease in grade III tumors. Keratin 13 showed a drastic decrease in grade IV tumors. In addition to identifying biomarkers that may have prognostic value, our studies have suggested that A-FABP is an important component of the pathway(s) leading to bladder cancer development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840999

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Current perspectives in cancer proteomics.

Authors:  Miriam V Dwek; Sarah L Rawlings
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

2.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

Authors:  Y F Guan; Y H Zhang; R M Breyer; L Davis; M D Breyer
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Loss of 15-hydroxyprostaglandin dehydrogenase expression disrupts urothelial differentiation.

Authors:  Stephanie Tseng-Rogenski; I-Ling Lee; Daniel Gebhardt; Susan M Fischer; Christopher Wood; John M Park; Monica Liebert
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

4.  Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Authors:  Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2009-11-23       Impact factor: 6.603

Review 5.  15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.

Authors:  Hsin-Hsiung Tai; Min Tong; Yunfei Ding
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-01-17       Impact factor: 3.072

6.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

7.  Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.

Authors:  José M A Moreira; Gita Ohlsson; Pavel Gromov; Ronald Simon; Guido Sauter; Julio E Celis; Irina Gromova
Journal:  Mol Cell Proteomics       Date:  2009-09-25       Impact factor: 5.911

8.  B-FABP-expressing radial glial cells: the malignant glioma cell of origin?

Authors:  Raja Mita; Jeffrey E Coles; Darryl D Glubrecht; Rohyun Sung; Xuejun Sun; Roseline Godbout
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

9.  Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.

Authors:  Stephanie Tseng-Rogenski; Jason Gee; Kathleen Woods Ignatoski; Lakshmi P Kunju; Amanda Bucheit; Hallie J Kintner; David Morris; Christopher Tallman; Joshua Evron; Christopher G Wood; H Barton Grossman; Cheryl T Lee; Monica Liebert
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

10.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.